This clinical trial focuses on people with Type 2 Diabetes who are overweight and currently using insulin. The study examines the effectiveness of combining two medications: semaglutide (Ozempic) and a reduced dose of insulin glargine (Lantus), compared to using a higher dose of insulin glargine alone.
The trial investigates whether using semaglutide along with a lower dose of insulin can control blood sugar levels just as effectively as using a higher dose of insulin by itself. Both medications are given through subcutaneous injection (under the skin) using pre-filled injection pens. The semaglutide is given once weekly, while insulin glargine is administered once daily.
The study lasts for 40 weeks and involves measuring changes in HbA1c (a measure of average blood sugar levels over the past 2-3 months). Participants will receive either a combination of semaglutide with reduced insulin glargine or insulin glargine alone. The study also looks at changes in body weight and how satisfied participants are with their treatment.



Czechia
Greece
Italy
Portugal
Romania
Slovakia
Spain